Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted) (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.83 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 12.16% to -$0.83 in Q4 2025 year-over-year; TTM through Nov 2025 was -$3.05, a 5.9% decrease, with the full-year FY2025 number at -$3.05, down 5.9% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.83 for Q4 2025 at Nurix Therapeutics, up from -$1.03 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.45 in Q2 2023 to a low of -$1.03 in Q3 2025.
  • A 5-year average of -$0.76 and a median of -$0.75 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 68.33% in 2022, then skyrocketed 55.45% in 2023.
  • Nurix Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.85 in 2021, then grew by 0.0% to -$0.85 in 2022, then increased by 9.41% to -$0.77 in 2023, then grew by 3.9% to -$0.74 in 2024, then fell by 12.16% to -$0.83 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's EPS (Weighted Average and Diluted) are -$0.83 (Q4 2025), -$1.03 (Q3 2025), and -$0.52 (Q2 2025).